![Beth Keyt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Beth Keyt
Consigliere Generale presso PEAR THERAPEUTICS, INC.
Profilo
Beth Keyt is currently the Vice President of Government Affairs and Market Access at Pear Therapeutics, Inc. She previously worked as the Senior Director of US Government at DexCom, Inc. Ms. Keyt received an undergraduate degree from the University of Connecticut.
Posizioni attive di Beth Keyt
Società | Posizione | Inizio |
---|---|---|
PEAR THERAPEUTICS, INC. | Consigliere Generale | - |
Precedenti posizioni note di Beth Keyt
Società | Posizione | Fine |
---|---|---|
DEXCOM, INC. | Corporate Officer/Principal | - |
Formazione di Beth Keyt
University of Connecticut | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
DEXCOM, INC. | Health Technology |
Aziende private | 1 |
---|---|
Pear Therapeutics, Inc.
![]() Pear Therapeutics, Inc. Medical SpecialtiesHealth Technology Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Beth Keyt